期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

用于心绞痛的代谢性治疗药物 被引量：2

Study of Metabolic Agents for Angina Pectoris
下载PDF
导出
摘要 心肌缺血通常导致一系列的代谢变化 ,改善缺血心肌的代谢 ,能改善心肌功能 ,因而可通过干预心肌代谢 ,治疗缺血性心脏病。本文介绍若干代谢性治疗药物对心绞痛的治疗作用、作用机制以及该类药物的开发前景。 Myocardial ischemia often leads to a series of metabolic changes. Metabolic management of myocardial ischemia may improve myocardial functions. Therefore, metabolic intervention is a valid approach to the treatment of ischemic heart diseases. The effects of several metabolic agents and their mechanisms of action were discussed here, and the prospect of the development of novel metabolic agents for the treatment of angina pectoris was appraised.
作者 汪送来 金熔 石文斌 王尔华
机构地区 中国药科大学医药化工研究所 青岛市立医院药剂科
出处 《药学进展》 CAS 2001年第6期348-351,共4页 Progress in Pharmaceutical Sciences
关键词 代谢性治疗药物 心绞痛 心肌缺血 心肌代谢 丙酸脱氢酶 曲美他嗪 雷诺嗪 Metabolic agent Angina pectoris Myocardial ischemia Myocardial metabolism PDH
分类号 R972 [医药卫生—药品]
  • 相关文献

参考文献24

  • 1[1]Kantor PF, Lucien A, Kozak R,et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase[J]. Circ Res,2000,86(5):580-588.
  • 2[2]Detry JM. Clinical features of an anti-anginal drug in angina pectoris[J]. Eur Heart J, 1993, 14 (Suppl G): 18-24.
  • 3[3]Desideri A, Celegon L. Metabolic management of ischemic heart disease: clinical data with trimetazidine[J]. Am J Cardiol, 1998,82 (5A) : 50K-53K.
  • 4[4]Zhiliaev EV, Urzhumova TV, Glazunov AV, et al. Clinical aspects of trimetazidine (preductal) administration as an antianglnal drug[J]. Ter Arkh, 2000,72(8): 20-23.
  • 5[5]Marzilli M. Clinical benefits of a metabolic approach in the management of coronary patients[J]. Rev Port Cardiol, 2000,19 (Suppl 5):V25-V30.
  • 6[6]Zacharowski K, Blackburn B, Thiemermann C. Ranolazine,a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat[J]. Eur J Pharmacol, 2001,418(1-2): 105-110.
  • 7[7]Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism[J]. J Mol Cell Cardiol, 1996,28(2): 341-350.
  • 8[8]Jain D, Dasgupta P, Hughes LO, et al. Ranolazine (RS43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium[J]. Eur J Clin Pharmacol, 1990,38(2): 111-114.
  • 9[9]Wang JX, Maruyama K, Murakami M. et al. Antianginal effects of ranolazine in various experimental models of angina[J]. Arzneimittelforschung, 1999,49(3): 193-199.
  • 10[10]Gralinski MR, Chi L, Park JL. et al. Protective effects of Ranolazine on ventricular fibrillation induced by activation of the ATP-dependentpotassiumchannel in the rabbit heart [J]. J Cardiovasc Pharmacol Ther, 1996,1(2): 141-148.

同被引文献9

引证文献2

二级引证文献51

药学进展
2001年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部